铁过载治疗的新靶点：第56届美国血液学会年会报道  

New progress of novel targets for iron overload in the 56th American Society of Hematology annual meeting

作　　者：唐旭东[1] 张路[2] 刘锋[3] 

机构地区：[1]中国中医科学院西苑医院血液科,100091 [2]中国中医科学院博士后科研流动站 [3]北京中医药大学管理学院

出　　处：《白血病．淋巴瘤》2015年第4期211-213,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学青年基金（81303127）;中国博士后科学基金（2014M551002）;国家中医药管理局行业科研专项（201107001）

摘　　要：介绍第56届美国血液学会（ASH）年会有关铁过载治疗的新靶点.铁沉积是β-地中海贫血和遗传性血色病的主要致死原因.这两种疾病的铁调素水平下调促进了铁的吸收,导致很多器官出现铁蓄积毒性.有研究指出,阻止铁吸收有助于减轻或阻止这两种疾病的铁过载.新的研究方向是Tmprss6,其主要抑制铁调素的表达.其他治疗方向包括减轻-地中海贫血的无效红细胞生成和贫血,因为红细胞生成旺盛抑制铁调素表达.文章主要讨论了控制铁代谢和红细胞生成的关键因素,探讨减轻或阻止这两种疾病的铁过载和减轻β-地中海贫血的贫血症状的新方法.New progress of guidelines for novel targets to iron overload in the 56th American Society of Hematology （ASH） annual meeting was reviewed.β-thalassemia and hereditary hemochromatosis disorders,and inappropriately low levels of the liver hormone hepcidin are responsible for the increased iron absorption,leading to toxic iron accumulation in many organs.Several studies have shown that targeting iron absorption could be beneficial to reducing or preventing iron overload in these 2 disorders.New approaches target Tmprss6.Additional strategies in β-thalassemia are showing beneficial effects in ameliorating ineffective erythropoiesis and anemia.The goal of this review is to discuss the major factors controlling iron metabolism and erythropoiesis and to discuss potential novel therapeutic approaches to reduce or prevent iron overload in these 2 disorders and ameliorate anemia in β-thalassemia.

关 键 词：铁过载 新靶点 美国血液学会年会 

分 类 号：R556.61[医药卫生—血液循环系统疾病]